脂氧素及其受体在消化系统疾病中的研究进展
|
摘要
脂氧素(lipoxins,LXs)是花生四烯酸的代谢产物,具有独特的抗炎和促炎症消退的作用,而这一效应主要是由脂氧素受体所介导,同时,脂氧素及其受体在肿瘤的生物学特征中也发挥着重要作用。近年来,脂氧素因其在消化系统疾病中的保护作用而引起广泛关注,对于脂氧素及其受体机制和生物学功能的深入探索,可为人类疾病的治疗和预防提供新的途径和方法。
引文
[1] Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes[J]. Proc Natl Acad Sci U S A,1984,81(17):5335-5339.
[2] Serhan CN, Chiang N. Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entree for resoleomics[J]. Rheum Dis Clin North Am,2004,30(1):69-95.
[3] Wallace JL. Eicosanoids in the gastrointestinal tract[J]. Br J Pharmacol,2018[Epub ahead of print].
[4] Wallace JL, de Lima OJ, Fiorucci S. Lipoxins in gastric mucosal health and disease[J]. Prostaglandins Leukot Essent Fatty Acids,2005,73(3/4):251-255.
[5] Fiorucci S, Distrutti E, de Lima OM, et al. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin[J]. FASEB J,2003,17(9):1171-1173.
[6] Pajdo R, Brzozowski T, Szlachcic A, et al. Lipoxins, the novel mediators of gastroprotection and gastric adaptation to ulcerogenic action of aspirin[J]. Curr Pharm Des,2011,17(16):1541-1551.
[7] Dai J, Shen J, Pan W, et al. Effects of polyunsaturated fatty acids on the growth of gastric cancer cells in vitro[J]. Lipids Health Dis,2013,12:71.
[8] Agis ER, Savas B, Melli M. Impact of colonic mucosal lipoxin A4 synthesis capacity on healing in rats with dextran sodium sulfate-induced colitis[J]. Prostaglandins Other Lipid Mediat,2015,121(Pt A):63-69.
[9] Vong L, Ferraz JG, Dufton N, et al. Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis[J]. PLoS One,2012,7(6):e39244.
[10] Janakiram NB, Mohammed A, Rao CV. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer[J]. Cancer Metastasis Rev,2011,30(3/4):507-523.
[11] Zhong X, Lee HN, Surh YJ. RvD1 inhibits TNFα-induced c-Myc expression in normal intestinal epithelial cells and destabilizes hyper-expressed c-Myc in colon cancer cells[J]. Biochem Biophys Res Commun,2018,496(2):316-323.
[12] Janakiram NB, Rao CV. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer[J]. Curr Mol Med,2009,9(5):565-579.
[13] Zhang C, Yu H, Ni X, et al. Growth inhibitory effect of polyunsaturated fatty acids (PUFAs) on colon cancer cells via their growth inhibitory metabolites and fatty acid composition changes[J]. PLoS One,2015,10(4):e123256.
[14] Tian R, Zuo X, Jaoude J, et al. ALOX15 as a suppressor of inflammation and cancer: Lost in the link[J]. Prostaglandins Other Lipid Mediat,2017,132:77-83.
[15] 张建,徐芬,郝华. 脂加氧酶表达与肿瘤及炎症性疾病关系的研究进展[J]. 临床与实验病理学杂志,2017,33(6):666-668.
[16] Yan D, Liu HL, Yu ZJ, et al. BML-111 Protected LPS/D-GalN-Induced Acute Liver Injury in Rats[J]. Int J Mol Sci,2016,17(7):E1114.
[17] Xia J, Zhou XL, Zhao Y, et al. Roles of lipoxin A4 in preventing paracetamol-induced acute hepatic injury in a rabbit model[J]. Inflammation,2013,36(6):1431-1439.
[18] El-Tanbouly GS, El-Awady MS, Megahed NA, et al. The lipoxin A4 agonist BML-111 attenuates acute hepatic dysfunction induced by cecal ligation and puncture in rats[J]. Naunyn Schmiedebergs Arch Pharmacol,2017,390(4):361-368.
[19] Zhou XY, Yu ZJ, Yan D, et al. BML-111, a lipoxin receptor agonist, protected carbon tetrachloride-induced hepatic fibrosis in rats[J]. Inflammation,2013,36(5):1101-1106.
[20] Hu Q, Hu Z, Chen Q, et al. BML-111 equilibrated ACE-AngII-AT1R and ACE2-Ang-(1-7)-Mas axis to protect hepatic fibrosis in rats[J]. Prostaglandins Other Lipid Mediat,2017,131:75-82.
[21] Hao H, Liu M, Wu P, et al. Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment[J]. Cancer Lett,2011,309(1):85-94.
[22] Zhou XY, Li YS, Wu P, et al. Lipoxin A(4) inhibited hepatocyte growth factor-induced invasion of human hepatoma cells[J]. Hepatol Res,2009,39(9):921-930.
[23] Xu F, Zhou X, Hao J, et al. Lipoxin A4 and its analog suppress hepatocarcinoma cell epithelial-mesenchymal transition, migration and metastasis via regulating integrin-linked kinase axis[J]. Prostaglandins Other Lipid Mediat, 2018,137:9-19.
[24] Yang F, Xie J, Wang W, et al. Regional arterial infusion with lipoxin A4 attenuates experimental severe acute pancreatitis[J]. PLoS One,2014,9(9):e108525.
[25] Lv W, Lv C, Yu S, et al. Lipoxin A4 attenuation of endothelial inflammation response mimicking pancreatitis-induced lung injury[J]. Exp Biol Med (Maywood),2013,238(12):1388-1395.
[26] Zhou M, Chen B, Sun H, et al. The protective effects of Lipoxin A4 during the early phase of severe acute pancreatitis in rats[J]. Scand J Gastroenterol,2011,46(2):211-219.
[27] 周春华, 王少峰, 呼闯营, 等. 脂氧素A4类似物对急性胰腺炎大鼠的保护作用及其机制[J]. 中华医学杂志,2012,92(14):993-998.
[28] Zong L, Li J, Chen X, et al. Lipoxin A4 Attenuates Cell Invasion by Inhibiting ROS/ERK/MMP Pathway in Pancreatic Cancer[J]. Oxid Med Cell Longev,2016,2016:6815727.
[29] Zong L, Chen K, Jiang Z, et al. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-beta1 signaling in pancreatic cancer[J]. J Exp Clin Cancer Res,2017,36(1):181.
[30] Schnittert J, Heinrich MA, Kuninty PR, et al. Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer[J]. Cancer Lett, 2018,427(28):247-258.
[2] Serhan CN, Chiang N. Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entree for resoleomics[J]. Rheum Dis Clin North Am,2004,30(1):69-95.
[3] Wallace JL. Eicosanoids in the gastrointestinal tract[J]. Br J Pharmacol,2018[Epub ahead of print].
[4] Wallace JL, de Lima OJ, Fiorucci S. Lipoxins in gastric mucosal health and disease[J]. Prostaglandins Leukot Essent Fatty Acids,2005,73(3/4):251-255.
[5] Fiorucci S, Distrutti E, de Lima OM, et al. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin[J]. FASEB J,2003,17(9):1171-1173.
[6] Pajdo R, Brzozowski T, Szlachcic A, et al. Lipoxins, the novel mediators of gastroprotection and gastric adaptation to ulcerogenic action of aspirin[J]. Curr Pharm Des,2011,17(16):1541-1551.
[7] Dai J, Shen J, Pan W, et al. Effects of polyunsaturated fatty acids on the growth of gastric cancer cells in vitro[J]. Lipids Health Dis,2013,12:71.
[8] Agis ER, Savas B, Melli M. Impact of colonic mucosal lipoxin A4 synthesis capacity on healing in rats with dextran sodium sulfate-induced colitis[J]. Prostaglandins Other Lipid Mediat,2015,121(Pt A):63-69.
[9] Vong L, Ferraz JG, Dufton N, et al. Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis[J]. PLoS One,2012,7(6):e39244.
[10] Janakiram NB, Mohammed A, Rao CV. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer[J]. Cancer Metastasis Rev,2011,30(3/4):507-523.
[11] Zhong X, Lee HN, Surh YJ. RvD1 inhibits TNFα-induced c-Myc expression in normal intestinal epithelial cells and destabilizes hyper-expressed c-Myc in colon cancer cells[J]. Biochem Biophys Res Commun,2018,496(2):316-323.
[12] Janakiram NB, Rao CV. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer[J]. Curr Mol Med,2009,9(5):565-579.
[13] Zhang C, Yu H, Ni X, et al. Growth inhibitory effect of polyunsaturated fatty acids (PUFAs) on colon cancer cells via their growth inhibitory metabolites and fatty acid composition changes[J]. PLoS One,2015,10(4):e123256.
[14] Tian R, Zuo X, Jaoude J, et al. ALOX15 as a suppressor of inflammation and cancer: Lost in the link[J]. Prostaglandins Other Lipid Mediat,2017,132:77-83.
[15] 张建,徐芬,郝华. 脂加氧酶表达与肿瘤及炎症性疾病关系的研究进展[J]. 临床与实验病理学杂志,2017,33(6):666-668.
[16] Yan D, Liu HL, Yu ZJ, et al. BML-111 Protected LPS/D-GalN-Induced Acute Liver Injury in Rats[J]. Int J Mol Sci,2016,17(7):E1114.
[17] Xia J, Zhou XL, Zhao Y, et al. Roles of lipoxin A4 in preventing paracetamol-induced acute hepatic injury in a rabbit model[J]. Inflammation,2013,36(6):1431-1439.
[18] El-Tanbouly GS, El-Awady MS, Megahed NA, et al. The lipoxin A4 agonist BML-111 attenuates acute hepatic dysfunction induced by cecal ligation and puncture in rats[J]. Naunyn Schmiedebergs Arch Pharmacol,2017,390(4):361-368.
[19] Zhou XY, Yu ZJ, Yan D, et al. BML-111, a lipoxin receptor agonist, protected carbon tetrachloride-induced hepatic fibrosis in rats[J]. Inflammation,2013,36(5):1101-1106.
[20] Hu Q, Hu Z, Chen Q, et al. BML-111 equilibrated ACE-AngII-AT1R and ACE2-Ang-(1-7)-Mas axis to protect hepatic fibrosis in rats[J]. Prostaglandins Other Lipid Mediat,2017,131:75-82.
[21] Hao H, Liu M, Wu P, et al. Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment[J]. Cancer Lett,2011,309(1):85-94.
[22] Zhou XY, Li YS, Wu P, et al. Lipoxin A(4) inhibited hepatocyte growth factor-induced invasion of human hepatoma cells[J]. Hepatol Res,2009,39(9):921-930.
[23] Xu F, Zhou X, Hao J, et al. Lipoxin A4 and its analog suppress hepatocarcinoma cell epithelial-mesenchymal transition, migration and metastasis via regulating integrin-linked kinase axis[J]. Prostaglandins Other Lipid Mediat, 2018,137:9-19.
[24] Yang F, Xie J, Wang W, et al. Regional arterial infusion with lipoxin A4 attenuates experimental severe acute pancreatitis[J]. PLoS One,2014,9(9):e108525.
[25] Lv W, Lv C, Yu S, et al. Lipoxin A4 attenuation of endothelial inflammation response mimicking pancreatitis-induced lung injury[J]. Exp Biol Med (Maywood),2013,238(12):1388-1395.
[26] Zhou M, Chen B, Sun H, et al. The protective effects of Lipoxin A4 during the early phase of severe acute pancreatitis in rats[J]. Scand J Gastroenterol,2011,46(2):211-219.
[27] 周春华, 王少峰, 呼闯营, 等. 脂氧素A4类似物对急性胰腺炎大鼠的保护作用及其机制[J]. 中华医学杂志,2012,92(14):993-998.
[28] Zong L, Li J, Chen X, et al. Lipoxin A4 Attenuates Cell Invasion by Inhibiting ROS/ERK/MMP Pathway in Pancreatic Cancer[J]. Oxid Med Cell Longev,2016,2016:6815727.
[29] Zong L, Chen K, Jiang Z, et al. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-beta1 signaling in pancreatic cancer[J]. J Exp Clin Cancer Res,2017,36(1):181.
[30] Schnittert J, Heinrich MA, Kuninty PR, et al. Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer[J]. Cancer Lett, 2018,427(28):247-258.